DANA-FARBER CANCER INSTITUTE TO INVESTIGATE CHEMOKINE'S ANTICANCER COMPOUND

Chemokine Therapeutics has executed a material transfer agreement with the Dana-Farber Cancer Institute of Boston, Mass.

Chemokine will supply Dana-Farber with its lead anticancer compound, CTCE-9908, a chemokine CXCR4 antagonist. Oncologists at Dana-Farber will study the benefits of CTCE-9908 in a series of preclinical studies, investigating the drug's ability to inhibit the growth of a human brain cancer (glioblastoma) cells.

CTCE-9908 is an analog of stromal cell derived factors 1 (SDF-1) that blocks the biological activities of this chemokine. SDF-1 is involved in cancer angiogenesis and metastasis. In previous experimental studies, CTCE-9908 has been shown to reduce cancer metastases by up to 70 percent.